GLP-1 implant from Vivani Medical aims to help patients stay on treatment
Vivani Medical is developing a long-term semaglutide implant designed to help patients maintain weight loss and improve adherence to GLP-1 treatments. The company has partnered with Novo Nordisk to evaluate the device, which aims to replace frequent injections with a twice-yearly or annual implant.
Why it matters
This technology addresses the high discontinuation rates of popular weight-loss drugs, potentially improving long-term health outcomes for obesity and diabetes patients.
Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder.
The article provides a balanced business and health report on a new medical technology development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in